Literature DB >> 20599254

Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4.

Eginhard Waldkirch1, Stefan Uckert, Katja Sigl, Kristina Langnaese, Karin Richter, Christian G Stief, Markus A Kuczyk, Petter Hedlund.   

Abstract

OBJECTIVES: To investigate the expression of isoforms of the cyclic AMP (cAMP)-dependent protein kinase (cAK) in the transition zone of the human prostate and the functional significance of the enzyme in the control of prostate smooth muscle.
METHODS: Using Western blot analysis and immunohistochemistry, the expression and distribution in the prostate of cAKIalpha, cAKIbeta, cAKIIalpha, and cAKIIbeta in relation to alpha-actin and the phosphodiesterase PDE4 (types A and B) were investigated. The effects of the cAK inhibitor Rp-8-CPT-cAMPS on the reversion of the adrenergic tension of isolated prostate tissue induced by forskolin, rolipram, sodium nitroprusside (SNP), and tadalafil were examined by means of the organ bath technique.
RESULTS: Immunosignals specific for cAKIalpha, cAKIIalpha, and cAKIIbeta were observed in the smooth musculature and glandular structures of the prostate. Double stainings revealed the colocalization of alpha-actin and PDE4 with the cAK isoforms. The expression of the cAK isoforms was confirmed by Western blot analysis. The relaxation of the tension induced by norepinephrine brought about by forskolin, rolipram, SNP, and tadalafil was significantly attenuated by Rp-8-CPT-cAMPS.
CONCLUSIONS: The colocalization of smooth muscle alpha-actin and PDE4 with cAK, as well as the results from the organ bath experiments, provide further evidence for a pivotal role of the cAMP-dependent signaling in the regulation of prostate smooth muscle contractility. Compounds interacting with the cAMP/cAK pathway might represent a new therapeutic avenue to treat symptoms of benign prostatic hyperplasia and lower urinary tract symptomatology. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20599254     DOI: 10.1016/j.urology.2010.04.035

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  9 in total

1.  Protein kinase enzymes in the human vagina-relation to key mediators of the cyclic AMP and cyclic GMP pathways.

Authors:  S Ückert; J Sonnenberg; J E Sonnenberg; W Kauffels; K Albrecht; M A Kuczyk; P Hedlund
Journal:  Int J Impot Res       Date:  2017-04-13       Impact factor: 2.896

2.  Soluble adenylyl cyclase mediates bicarbonate-dependent corneal endothelial cell protection.

Authors:  Shimin Li; Kah Tan Allen; Joseph A Bonanno
Journal:  Am J Physiol Cell Physiol       Date:  2010-12-01       Impact factor: 4.249

Review 3.  Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction.

Authors:  Stefan Uckert; Matthias Oelke
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

Review 4.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

5.  Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.

Authors:  Ana M Peiró; Chih-Min Tang; Fiona Murray; Lingzhi Zhang; Loren M Brown; Daisy Chou; Laura Rassenti; Thomas J Kipps; Thomas A Kipps; Paul A Insel
Journal:  J Hum Genet       Date:  2011-07-28       Impact factor: 3.172

6.  Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate.

Authors:  Stefan Ückert; Eginhard S Waldkirch; Axel S Merseburger; Markus A Kuczyk; Matthias Oelke; Petter Hedlund
Journal:  World J Urol       Date:  2013-03-09       Impact factor: 4.226

7.  The cAMP effector EPAC activates Elk1 transcription factor in prostate smooth muscle, and is a minor regulator of α1-adrenergic contraction.

Authors:  Martin Hennenberg; Frank Strittmatter; Henning Schmetkamp; Beata Rutz; Sebastian Walther; Christian G Stief; Christian Gratzke
Journal:  J Biomed Sci       Date:  2013-07-02       Impact factor: 8.410

8.  Pharmacology of the lower urinary tract.

Authors:  Martin Hennenberg; Christian G Stief; Christian Gratzke
Journal:  Indian J Urol       Date:  2014-04

9.  Phosphodiesterase type 4 inhibition enhances nitric oxide- and hydrogen sulfide-mediated bladder neck inhibitory neurotransmission.

Authors:  Ángel Agis-Torres; Paz Recio; María Elvira López-Oliva; María Pilar Martínez; María Victoria Barahona; Sara Benedito; Salvador Bustamante; Miguel Ángel Jiménez-Cidre; Albino García-Sacristán; Dolores Prieto; Vítor S Fernandes; Medardo Hernández
Journal:  Sci Rep       Date:  2018-03-16       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.